Ascentage Pharma Group International (AAPG)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Ascentage Pharma Group International (AAPG) is down 31.9% since the beginning of the year. At $18 per share, AAPG is trading 63.1% below its 52-week high of $48.

Ascentage Pharma Group International (AAPG) has returned -31.90% so far this year and -35.60% over the past 12 months.

Based on dividend-adjusted daily data since Jan 24, 2025, AAPG's average daily return is +0.09%, while the average monthly return is +1.39%. At this rate, an investment would double in approximately 4.2 years.

Historically, 33% of months were positive and 67% were negative. The best month was Jun 2025 with a return of +61.4%, while the worst month was Dec 2025 at -19.3%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 10 months.

On a daily basis, AAPG closed higher 50% of trading days. The best single day was Mar 23, 2026 with a return of +16.8%, while the worst single day was Mar 20, 2026 at -13.3%.

Ascentage Pharma Group International has an annualized alpha of 9.87%, beta of 0.73, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since January 27, 2025.

• This stock captured 5.96% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -0.38%) - a profile typical of hedging or uncorrelated assets.
• R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

AAPG ranks 20 for risk / return — in the bottom 20% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for Ascentage Pharma Group International (AAPG) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Ascentage Pharma Group International. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Ascentage Pharma Group International was 62.69%, occurring on Jun 3, 2026. The portfolio has not yet recovered.

The current Ascentage Pharma Group International drawdown is 62.69%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Ascentage Pharma Group International over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Ascentage Pharma Group International is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.